应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ANRO Alto Neuroscience Inc
盘前交易 05-20 08:28:46 EDT
12.47
-0.35
-2.73%
最高
13.07
最低
12.17
成交量
8.90万
今开
12.92
昨收
12.82
日振幅
6.98%
总市值
3.35亿
流通市值
2.41亿
总股本
2,686万
成交额
111.22万
换手率
0.46%
流通股本
1,931万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美国研究综述-Agiliti、Domino's、Krystal 生物技术公司
Reuters · 02-27
美国研究综述-Agiliti、Domino's、Krystal 生物技术公司
美国研究综述-Agiliti、多米诺比萨、Krystal 生物技术公司
Reuters · 02-27
美国研究综述-Agiliti、多米诺比萨、Krystal 生物技术公司
药物研发公司Alto纽交所上市:首日上涨29% 公司市值5亿美元
雷递 · 02-03
药物研发公司Alto纽交所上市:首日上涨29% 公司市值5亿美元
公司概况
公司名称:
Alto Neuroscience Inc
所属市场:
NYSE
上市日期:
--
主营业务:
Alto Neuroscience, Inc.于2019年3月25日在特拉华州注册成立。公司总部设在加州洛斯阿尔托斯。该公司是一家临床阶段的生物制药公司,其使命是通过利用神经生物学来开发个性化和高效的治疗方案,重新定义精神病学。在其创始人Amit Etkin博士十多年的研究基础上,他们的目标是深入了解大脑功能,并通过使用针对特定患者群体的治疗方法,更有效地为患者匹配正确的药物。他们目前的产品线包括五个临床阶段的资产,最初针对重度抑郁症(MDD)和精神分裂症人群,这些人群具有独立的基于大脑的生物标志物。他们的每一种临床阶段候选产品都至少通过初始1期临床试验进行评估,并观察到耐受性良好。该公司最先进的项目,包括正在进行的后期(2b或更晚)试验评估的两个候选产品,都得到了生物标志物特征人群临床活性的前瞻性重复证据的支持。
发行价格:
--
{"stockData":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience Inc","latestPrice":12.47,"timestamp":1715976000000,"preClose":12.82,"halted":0,"volume":89015,"delay":0,"floatShares":19308261,"shares":26862913,"eps":-5.88742,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.35,"latestTime":"05-20 08:28:46 EDT","open":12.92,"high":13.065,"low":12.17,"amount":1112216.07656,"amplitude":0.069813,"askPrice":17.36,"askSize":100,"bidPrice":4.99,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-5.88742,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716211800000},"adr":0,"listingDate":1706850000000,"adjPreClose":12.47,"postHourTrading":{"tag":"盘后","latestPrice":12.47,"preClose":12.47,"latestTime":"16:00 EDT","volume":27,"amount":336.96,"timestamp":1715976005393},"volumeRatio":1.013012167177443},"requestUrl":"/m/hq/s/ANRO/wiki","defaultTab":"wiki","newsList":[{"id":"2414738998","title":"美国研究综述-Agiliti、Domino's、Krystal 生物技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2414738998","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414738998?lang=zh_cn&edition=full","pubTime":"2024-02-27 19:35","pubTimestamp":1709033708,"startTime":"0","endTime":"0","summary":" 路透社2月27日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括 Agiliti、多米诺比萨和 Krystal Biotech。公司要闻 * Agiliti Inc :杰富瑞将其评级从 \"买入 \"下调至 \"持有 * Autodesk Inc :加拿大皇家银行将目标价从280美元上调至290美元 * Domino's Pizza Inc :杰富瑞将目标价从400美元上调至455美元 * Itron Inc :Canaccord Genuity将目标价从68美元上调至105美元 * Krystal Biotech Inc :Evercore ISI将该股从战术跑赢大盘名单中除名 以下是路透社周二报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414849832","title":"美国研究综述-Agiliti、多米诺比萨、Krystal 生物技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2414849832","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414849832?lang=zh_cn&edition=full","pubTime":"2024-02-27 15:31","pubTimestamp":1709019083,"startTime":"0","endTime":"0","summary":" 路透社2月27日 - 华尔街证券分析师周二调整了对 Agiliti、多米诺比萨和 Krystal Biotech 等几家美国上市公司的评级和目标价。公司要闻 * Agiliti公司 :杰富瑞将其评级从 \"买入 \"下调至 \"持有 * 多米诺比萨 :杰富瑞将目标价从400美元上调至455美元 * Krystal Biotech Inc :Evercore ISI将其股票从战术跑赢大盘名单中除名 以下是路透社周二报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408996984","title":"药物研发公司Alto纽交所上市:首日上涨29% 公司市值5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2408996984","media":"雷递","top":-1,"share":"https://www.laohu8.com/m/news/2408996984?lang=zh_cn&edition=full","pubTime":"2024-02-03 10:56","pubTimestamp":1706928977,"startTime":"0","endTime":"0","summary":"Alto上市发行价为16美元,发行804万股,募资总额为1.286亿美元。Alto开盘价为22美元,较发行价上涨37.5%;收盘价为20.7美元,较发行价上涨29%;以收盘价计算,公司市值5亿美元。Alto Neuroscience在2023年前9个月净亏损为2509万美元,上年同期的净亏损为2006万美元。累计募资超1亿美元成立以来,Alto Neuroscience已完成超过1亿美元的融资。其中,2023年1月,Alto Neuroscience宣布完成2500万美元股权投资,这使得B轮融资总额达6000万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240203105925816679ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240203105925816679ec&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.altoneuroscience.com","stockEarnings":[{"period":"1week","weight":-0.0756},{"period":"1month","weight":-0.0749},{"period":"3month","weight":-0.2137},{"period":"6month","weight":-0.2206},{"period":"ytd","weight":-0.2206}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alto Neuroscience, Inc.于2019年3月25日在特拉华州注册成立。公司总部设在加州洛斯阿尔托斯。该公司是一家临床阶段的生物制药公司,其使命是通过利用神经生物学来开发个性化和高效的治疗方案,重新定义精神病学。在其创始人Amit Etkin博士十多年的研究基础上,他们的目标是深入了解大脑功能,并通过使用针对特定患者群体的治疗方法,更有效地为患者匹配正确的药物。他们目前的产品线包括五个临床阶段的资产,最初针对重度抑郁症(MDD)和精神分裂症人群,这些人群具有独立的基于大脑的生物标志物。他们的每一种临床阶段候选产品都至少通过初始1期临床试验进行评估,并观察到耐受性良好。该公司最先进的项目,包括正在进行的后期(2b或更晚)试验评估的两个候选产品,都得到了生物标志物特征人群临床活性的前瞻性重复证据的支持。","exchange":"NYSE","name":"Alto Neuroscience Inc","nameEN":"Alto Neuroscience Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alto Neuroscience Inc(ANRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alto Neuroscience Inc(ANRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alto Neuroscience Inc,ANRO,Alto Neuroscience Inc股票,Alto Neuroscience Inc股票老虎,Alto Neuroscience Inc股票老虎国际,Alto Neuroscience Inc行情,Alto Neuroscience Inc股票行情,Alto Neuroscience Inc股价,Alto Neuroscience Inc股市,Alto Neuroscience Inc股票价格,Alto Neuroscience Inc股票交易,Alto Neuroscience Inc股票购买,Alto Neuroscience Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alto Neuroscience Inc(ANRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alto Neuroscience Inc(ANRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}